MDX-240 bispecific antibody data

In a Phase I/II dose escalating trial in 12 HIV-infected patients with CD4 counts of <400, MDX-240 was well-tolerated and induced a transient increase of 30-225 CD4 cells in 4 patients. In the remaining 8 patients, CD4 counts remained stable, with viral level remaining stable in all patients.

The bispecific antibody binds both the high affinity Fc receptor for IgG and the HIV envelope protein, gp41. ...